logo
logo
SRDX stock ticker logo

Surmodics, Inc.

NASDAQ•SRDX
CEO: Mr. Gary R. Maharaj
板块: Healthcare
行业: Medical - Devices
上市日期: 1998-03-04
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
联系方式
9924 West 74th Street, Eden Prairie, MN, 55344-3523, United States
952-500-7000
www.surmodics.com
市值
$614.51M
市盈率 (TTM)
-34.8
30
股息率
--
52周最高
$43.00
52周最低
$25.87
52周范围
100%
排名49Top 66.7%
3.2
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
疲弱 • 3.2 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025

财务仪表盘

Q3 2025 数据

营业收入

$29.57M-2.55%
近4季度走势

每股收益

-$0.37-30.19%
近4季度走势

自由现金流

$904.00K-130.21%
近4季度走势

2025 Q3 财报亮点

核心亮点

Nine Month Revenue Decline Nine month total revenue $87.6M, reflecting a 6% decrease from prior period levels.
Net Loss Widens Significantly Net loss reached $(14.2M) for nine months, significantly wider than prior year's $(8.1M).
Medical Device Sales Drop Medical Device product sales $27.4M, down 19% driven by SurVeil DCB shipment decrease.
Merger Charges Inflate SG&A SG&A expense increased 14% to $48.0M, primarily due to $10.1M in merger-related charges.

关注风险

SurVeil DCB Revenue Forecast SurVeil DCB revenue forecast decline of $7.5M in fiscal 2025, offsetting Pounce platform growth.
FTC Merger Litigation Risk Consummation of pending acquisition remains subject to resolution of FTC litigation proceedings.
Recent Cyber Security Incident Experienced June 2025 cyber incident; incurred $1.9M response costs with ongoing reputation risks.
Product Gross Margin Pressure Product gross margin compressed 460 basis points to 50.7% due to SurVeil under-absorption issues.

前瞻展望

2025 Liquidity Sufficiency Existing cash ($32.7M) and credit facility expected to fund 2025 operations and capital expenditures.
Continued Gross Profit Decline Product gross profit and margin expected to decline further due to SurVeil DCB revenue decline.
High Near-Term Expenses SG&A and R&D expenses remain significant, driven by merger charges and Pounce/Sublime platform investment.
Future Financing Potential Long-term cash needs depend on commercialization success; may seek debt or equity financing later.

同行对比

营业收入 (TTM)

VREX stock ticker logoVREX
$854.40M
+4.1%
CCRN stock ticker logoCCRN
$817.53M
-39.2%
BVS stock ticker logoBVS
$568.09M
-0.9%

毛利率 (最新季度)

SMLR stock ticker logoSMLR
91.5%
+0.1pp
XOMA stock ticker logoXOMA
90.6%
-9.4pp
DCTH stock ticker logoDCTH
85.5%
+1.9pp

关键指标

股票代码
市值
市盈率 (TTM)
净资产收益率 (TTM)
负债率
TCMD$659.93M34.59.3%5.8%
SRDX$614.51M-34.8-15.6%19.2%
BVS$609.49M26.713.8%2.2%

长期趋势

近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
-3.8%
基本持平
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
75%
现金流波动较大

深度研究

下次财报:2026年4月28日
|
每股收益:-
|
营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据